Chinese biotech dominance in R&D is on the rise
Source: SeekingAlpha
2025-01-18 15:56:17 ET
More on AstraZeneca, Merck, etc.
- AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector
- Merck & Co. Inc. (MRK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
- AstraZeneca: Uncertainty Ahead, Neutral Rating Confirmed.
- AstraZeneca, Daiichi Sankyo antibody-drug conjugate Dato-DXd gains FDA nod
- AstraZeneca said to have changed management of its China unit
Read the full article on Seeking Alpha
For further details see:
Chinese biotech dominance in R&D is on the rise
Hansoh Pharmaceutical Gr
NASDAQ: HNSPF
HNSPF Trading
0.0% G/L:
$5.16 Last:
109 Volume:
$5.16 Open:
